Rigel Pharmaceuticals Inc...

17.63
-0.58 (-3.19%)
At close: Apr 03, 2025, 3:59 PM
17.10
-3.01%
Pre-market: Apr 04, 2025, 04:39 AM EDT
-3.19%
Bid 17.07
Market Cap 314.92M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) 0.99
PE Ratio (ttm) 17.81
Forward PE 18.78
Analyst Hold
Ask 18.5
Volume 154,738
Avg. Volume (20D) 246,138
Open 17.02
Previous Close 18.21
Day's Range 17.05 - 18.11
52-Week Range 7.48 - 29.82
Beta 1.32

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical t...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 29, 2000
Employees 162
Stock Exchange NASDAQ
Ticker Symbol RIGL
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for RIGL stock is "Hold." The 12-month stock price forecast is $25, which is an increase of 41.80% from the latest price.

Stock Forecasts

Next Earnings Release

Rigel Pharmaceuticals Inc. is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-8.11%
Rigel Pharmaceuticals shares are trading lower. Th... Unlock content with Pro Subscription
3 months ago
-11.23%
Rigel Pharmaceuticals shares are trading lower after B. Riley Securities cut its price target on the stock from $27 to $20.